Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

December 1, 2014 Pfizer Inc. today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. “NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines …

TRUMENBA (Meningococcal Group B Vaccine) is Now Available

November 18, 2014 Pfizer Inc. announced today that TRUMENBA® (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States. Serogroup B meningococcal meningitis is characterized by high fatality rates and …

On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015 November 17, 2014 Pfizer Inc. announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to …

The Most Influential People in Vaccines

Vaccine Nation presents the 50 most influential people in vaccines Download the Most Influential People in Vaccines to find out: Has Bill Gates lost his top spot? Who are the 25 new entries? Which disease field has produced the most influential experts Over the last two months we asked you to vote for who you believe are the three most influential …

Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation

August 28, 2014 Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C. difficile is a growing, difficult-to-treat healthcare-associated infection,” said Dr. Emilio …

Pfizer's Pneumococcal Vaccine Could See a Boost in Sales After the CDC's Recommendation for Use in Older Adults

Pfizer’s Prevnar 13 Could See a $2 Billion Boost in Sales

Pfizer’s Pneumococcal Vaccine Could See a Boost in Sales After the CDC’s Recommendation for Use in Older Adults On Wednesday, Pfizer announced that the CDC’s Advisory Committee on Immunisation Practices (ACIP) has decided to recommend and promote the Prevnar 13 pneumococcal vaccine for use in adults aged 65 and up. The vaccine protects against pneumococcal diseases including pneumonia, which can …

On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

August 14, 2014 Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the …

On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older

August 13, 2014 Pfizer Inc. today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. …

European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13 For Prevention Of Pneumococcal Pneumonia In Adults

August 7th, 2014 -Application Includes Data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted Pfizer’s application seeking to expand the indication for Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in …

Pfizer bid for GSK ‘has some merits’, says Berenberg

August 1st, 2014 Could Pfizer acquire GlaxoSmithKline as a “plan B” after failing to land AstraZeneca? It would be a stretch but not totally impossible, according to analysts at Berenberg Bank. GSK’s market capitalisation has slumped to $117 billion (£69.49 billion), or just under Pfizer’s failed offer for AstraZeneca, following weak quarterly results and a warning on full-year profits last …